Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Date of authorisation: 20/06/2019, Revision: 5,...
Overview Grasustek is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer chemotherapy and can leave patients vulnerable to infections. It is given …